DHONG, EUL WON,HU, HONG GU,KIM, HAE YANG,SHIN, HYE-GYEONG,PARK, HYO-JIN,PARK, SANG-GEUN
申请号：
CA3010857
公开号：
CA3010857C
申请日:
2016.12.16
申请国别(地区):
CA
年份:
2020
代理人:
摘要：
The present invention relates to a pharmaceutical composition having an improved dissolution rate of nebivolol. A pharmaceutical composition, containing nebivolol or a pharmaceutically acceptable salt thereof, an alkalizing agent, and a pharmaceutically acceptable additive, for prevention or treatment of cardiovascular diseases, does not cause a decrease in the dissolution rate of nebivolol and can significantly improve the dissolution rate, not only at low pH, such as pH 1.2, but also at a relatively high pH of 5 to 7, so that an improved therapeutic effect can be expected. In addition, the pharmaceutical composition can reduce the preparation cost since the micronization of nebivolol or the addition of a wetting agent is not required, and can minimize the occurrence of a deviation of bioavailability due to pre- or post-meal intake since there is little deviation of the dissolution rate due to the pH change, thereby maintaining a constant pharmaceutical action, and thus, the pharmaceutical composition is very useful in the preparation of a composite preparation containing a nebivolol preparation, or another active ingredient, such as rosuvastatin calcium.
